62nd ASH Annual Meeting and Exposition: 704. Immunotherapies: Poster II

Oral and Poster Abstracts
Poster

Adult, ALL, AML, antibodies, Biological, CRS, Leukemia, multiple myeloma, therapy sequence, CLL, Diseases, iPSCs, Lymphoma (any), neurotoxicity, CAR-Ts, Combinations, Therapies, Adverse Events, checkpoint inhibitors, MDS, Pediatric, B-Cell Lymphoma, Biological Processes, DLBCL, cell expansion, Immune Disorders, Technology and Procedures, Cell Lineage, immunotherapy, Infectious Diseases, Plasma Cell Disorders, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, NK cells, immune mechanism, stem cells

2345

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MD, PhD¹^*, Min Xiao²^*, Zekai Mao³^*, Na Wang, MD, PhD⁴^*, Chunrui Li, MD, PhD⁵, Yang Cao⁶^*, Weimin Sun³^*, Yi Xiao²^*, Chaojiang Gu⁷^*, Shangkun Zhang, PhD⁸^*, Yicheng Zhang⁹, Tongcun Zhang, Ph.D.⁷^*, Jianfeng Zhou, MD, PhD⁶^* and Liang Huang, MD⁶^*

¹Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, BALTIMORE, MD
²Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
³Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong Univ, Wuhan, CHN
⁴Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
⁵Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
⁶Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
⁷Wuhan University of Science and Technology, Wuhan, China
⁸Wuhan Bio-Raid Biotechnology CO., LTD., Wuhan, CHN
⁹Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, China

2346

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Jae H. Park, MD¹, Isabelle Riviere, PhD²^*, Devanjan S. Sikder²^*, Vladimir P. Bermudez²^*, Brigitte Senechal²^*, Xiuyan Wang, PhD²^*, Thomas H. Auchincloss³^*, Claudia Diamonte, RN³^*, Elizabeth Halton, NP-BC AOCNP³^*, M. Lia Palomba, MD⁴, Renier J. Brentjens, MD, PhD³ and Michel Sadelain, MD, PhD⁵

¹Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY
³Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Center for Cell Engineering and Immunology Program, Memorial Sloan Kettering Cancer Center, New York City, NY

2347

A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Sumithira Vasu, MD, MBBS¹, Bhavana Bhatnagar, DO², James S. Blachly, MD³, Nicole Szuminski, BS¹^*, Lynn O'Donnell, PhD⁴^* and Dean Anthony Lee, MD, PhD⁵

¹The Ohio State University, Columbus, OH
²Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
³Division of Hematology, The Ohio State University, Columbus, OH
⁴Comprehensive Cancer Center, Ohio State University Medical Center - James Cancer Hospital, Columbus, OH
⁵Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH

2348

Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis

Chantal Saberian, MD¹^*, Noha Abdel-Wahab²^*, Ala Abudayyeh, MD³^*, Hind Rafei, MD⁴^*, Jacinth Joseph, MD⁵^*, May Daher⁵, Stephen K. Gruschkus, PhD, MPH⁶^*, Cristina Knape⁷^*, Laura Whited⁸^*, Alison Gulbis⁹^*, Megan Marcotulli⁸^*, Gabriela Rondon¹⁰, Uday R. Popat, MD⁵, Rohtesh S. Mehta, MD, MPH, MS⁵, Marina Konopleva, MD, PhD¹¹, Betul Oran, MD, MS¹², Maro Ohanian, DO¹³^*, Farhad Ravandi, MBBS¹⁴, Guillermo Garcia-Manero, MD¹³, Amin M. Alousi, MD¹⁵, Naval Daver, MD¹³, Richard E. Champlin, MD¹⁰, Adi Diab, MD¹⁶^* and Gheath Alatrash¹⁷

¹Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX
²University of Texas MD Anderson Cancer Center, Houston, TX
³MD Anderson Cancer Center, Houston, TX
⁴Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
⁷The University of Texas MD Anderson Cancer Center, Houston, TX
⁸UT M.D. Anderson Cancer Center, Houston, TX
⁹Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁰Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
¹¹University of Texas, MD Anderson Cancer Center, Houston, TX
¹²Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX
¹³Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁴Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
¹⁵Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
¹⁶Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX
¹⁷Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

2349

Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Wei Liu¹^*, Wenyang Huang²^*, Ryu Lv¹^*, Shuhui Deng, MD²^*, Shuhua Yi, MD³^*, Huimin Liu¹^*, Lulu Lv⁴^*, Lugui Qiu, MD², Dehui Zou, MD³^* and Jianxiang Wang, MD¹

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, TIANJIN, China
⁴Juventas Cell Therapy Ltd., Tianjin, China

2350

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA¹^*, Todd Devries, PhD¹^*, Aditya Radhakrishnan, PhD¹^*, Yan Li, PhD¹^*, Mark Heipel, BS¹^*, Brian A. Fox, PhD²^*, Valeria Beckett, MS¹^*, Mariana Cota Stirner, MD, PhD¹, Kristin Conte, MPH¹^*, Thomas Doerr, MSc¹^*, Sham Mailankody, MBBS³, Sandy W. Wong, MD⁴ and Philip L. McCarthy, MD⁵

¹Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA
²Bristol-Myers Squibb Company, Princeton, NJ
³Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Tufts Medical Center, San Francisco, CA
⁵Roswell Park Cancer Institute, Buffalo, NY

2351

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD¹^*, Forat Lutfi, MD², Facundo Zafforoni, BS³^*, Moaath Mustafa Ali, MD, MPH²^*, Ali Bukhari, MD², David Gottlieb, MD²^*, Seung-Tae Lee, MD, PhD⁴^*, Mehmet Hakan Kocoglu, MD², Nancy M. Hardy, MD², Jean A. Yared, MD², Aaron P. Rapoport, MD², Jennie Y. Law, MD² and Saurabh Dahiya, MD²

¹Department of Medicine, University of Maryland Medical Center, Baltimore, MD
²Division of Hematology and Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
³European Organization for Research and Treatment of Cancer, Brussels, Belgium
⁴Division of Hematology/Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD

2352

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD¹, Bita Fakhri, MD, MPH², Ying Sheng³^*, Chiung-Yu Huang, PhD⁴^*, Sophia Byslma, BS⁵^*, Kelsey Natsuhara, MD⁵^*, Dhruba Biswas⁵^*, Mimi Lo, PharmD, BCPS, BCOP⁶^*, Weiyun Z. Ai⁷, Lawrence D Kaplan, MD⁸, Thomas Martin III, MD⁹, Jeffrey L. Wolf, MD⁹, Nina Shah, MD¹⁰, Charalambos Andreadis, MD, MSCE¹¹^* and Sandy W. Wong, MD¹²

¹Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA
²Division of Hematology and Oncology, University of California, San Francisco, CA
³University of California, San Francisco (UCSF), San Francisco, CA
⁴Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA
⁵University of California San Francisco, San Francisco
⁶Department of Pharmaceutical Services, University of California, San Francisco, San Francisco, CA
⁷Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA
⁸Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
⁹University of California, San Francisco, San Francisco, CA
¹⁰Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
¹¹Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
¹²Tufts Medical Center, San Francisco, CA

2353

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS¹^*, Rahul Banerjee, MD², Chiung-Yu Huang, PhD³^*, Mimi Lo, PharmD, BCPS, BCOP⁴^*, Vanessa E Kennedy, MD⁵, Shagun Arora, MD¹, Jeffrey L. Wolf, MD¹, Thomas Martin III, MD¹, Sandy W. Wong, MD¹ and Nina Shah, MD⁶

¹University of California, San Francisco, San Francisco, CA
²University of California, San Francisco, SAN FRANCISCO, CA
³University of California San Francisco, San Francisco, CA
⁴Department of Pharmaceutical Services, University of California, San Francisco, San Francisco, CA
⁵University of California- San Francisco, San Francisco, CA
⁶Associate Professor of Medicine, University of California San Francisco, San Francisco, CA

2354

Siglec-15 Is a Novel Immunomodulatory Protein and Therapeutic Target in Childhood Leukemia

Claire E. Pillsbury^1,2^*, Jairo A. Fonseca, MD¹^*, Jodi Dougan¹^*, Hasan Abukharma³^*, Linda N. Liu, PhD³^* and Christopher C. Porter, MD^1,2

¹Department of Pediatrics, Emory University, Atlanta, GA
²Cancer Biology Program, Emory University, Atlanta, GA
³NextCure, Inc., Beltsville, MD

2355

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Vanessa E Kennedy, MD¹, Christopher Wong²^*, Chiung-Yu Huang, PhD³^*, Jeffrey L. Wolf, MD⁴, Thomas Martin, MD⁵, Nina Shah, MD⁶ and Sandy W. Wong, MD⁷

¹University of California- San Francisco, San Francisco, CA
²School of Medicine, Touro University California, Vallejo, CA
³University of California, San Francisco, San Francisco
⁴University of California, San Francisco, San Francisco, CA
⁵University of California, San Francisco, CA
⁶Associate Professor of Medicine, University of California San Francisco, San Francisco, CA
⁷Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA

2356

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC‑Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD, PhD¹, Zuzan Cayci, MD²^*, Dixie Lewis, RN, BA³^*, Joseph E. Maakaron, MD¹, Murali Janakiram, MD⁴, Andersen Bartz³^*, Steven Payne, BS⁵^*, Carol Wong, MPH⁵^*, Sarah Cooley, MD⁵, Bahram Valamehr, PhD⁵, Yu-Waye Chu, MD⁵ and Jeffrey S. Miller, MD¹

¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
²Department of Radiology, University of Minnesota, Minneapolis, MN
³Masonic Cancer Center, University of Minnesota, Minneapolis, MN
⁴Division of Hematology, Oncology and Transplantation, University of Minnesota, Rochester, MN
⁵Fate Therapeutics, Inc., San Diego, CA

2357

Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma

Issa F. Khouri, MD¹, Denái R. Milton, MS²^*, Celina Ledesma³^*, Elias Jabbour, MD⁴, Qaiser Bashir³^*, Jin S. Im⁵, Luis Fayad⁶, Hun Ju Lee, MD⁷, Ranjit Nair⁷^*, Loretta J. Nastoupil, MD⁶, Felipe Samaniego, MD⁷, Swami P. Iyer, MD⁸, Christopher Flowers, MD, MS⁶, Richard E. Champlin, MD¹, Padmanee Sharma⁹^* and Alison Gulbis¹⁰^*

¹Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁶Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁷Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁸Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX
⁹Department of Immunology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
¹⁰Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH